Sarah Cannon Research Institute Adds Leadership to Its Global Services Division

NASHVILLE, Tenn.--(BUSINESS WIRE)-- The Global Services Division of Sarah Cannon Research Institute (SCRI) has named A. Collier Smyth, M.D., director, medical strategy; Debbie Haynes senior director, development strategy and operations; and Carol Greenlees, Ph.D., senior director, global clinical operations.

SCRI’s Global Services specializes in clinical research services with a focus on oncology drug development programs and works with investigative sites on a global platform. Available services as part of an integrated trial management program include project management, clinical monitoring, data management, biostatistics, safety, medical writing, quality assurance and data safety monitoring boards.

“These three life sciences leaders bring more than 50 years of combined experience to the SCRI team,” said Phil Cestaro, SCRI president, Global Services. “Their vast knowledge in international clinical trial strategy and execution will be a tremendous asset to our organization.”

Smyth is a member of the American Society of Clinical Oncology, the American Medical Association and the American College of Physician Executives. After more than 30 years of building and leading physician and pharmaceutical organizations devoted to oncology, Smyth retired from Bristol-Myers Squibb in March 2009.

During his 13-year tenure he held senior vice president and vice president positions in medical affairs and medical strategy. Smyth currently serves on the advisory board of Ken Clark International and on the board of directors of Ariad Pharmaceuticals, EpiCept Corporation and ClinOps LLC. He also consults with Poniard Pharmaceuticals.

Prior to joining Bristol-Myers Squibb, Smyth was vice president, medical affairs at American Oncology Resources (now US Oncology) in Houston and was founder and president of New Hampshire Oncology/Hematology.

Smyth received his bachelor’s degree from Lehigh University in Bethlehem, Pa. and medical degree from Johns Hopkins School of Medicine in Baltimore. He performed his internship and residency in medicine at Beth Israel Hospital and Harvard Medical School in Boston and completed his fellowship in oncology at Baltimore Cancer Research Center. He is board certified in internal medicine and medical oncology.

Haynes has 15 years of drug development experience and comes most recently from Genentech U.K.’s Office of International Development, where she was the regional head for Europe, Middle East and Africa. She also has held leadership positions in regulatory affairs with pharmaceutical companies Johnson & Johnson, Dainippon Sumitomo (where she was also responsible for clinical quality assurance and drug safety), Daiichi and Elan in the United Kingdom.

Haynes received her bachelor’s degree from Manchester University in the United Kingdom.

Greenlees has 13 years’ experience in clinical operations and program management for biotechnology companies and contract research organizations in the United Kingdom. Most recently, she was head of European clinical operations for Antisoma Research Limited, where she had oversight of the delivery of clinical trials in Europe, Asia Pacific, Latin America and the United States.

Greenlees earned her bachelor’s degree from University of Glasgow and holds a doctorate in cardiovascular pharmacology from University of Strathclyde in Glasgow.

SCRI is a strategic research organization focusing on advancing therapies and accelerating drug development. It is one of the largest clinical research programs in the nation, conducting community-based clinical trials in oncology, cardiology, gastroenterology and other therapeutic areas through affiliations with a network of more than 450 physicians in 24 states. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites across the country. For more information, please visit www.sarahcannonresearch.com.

Contact Nikki Klemmer at [email protected] for hi-res headshots.



CONTACT:

Atkinson Public Relations
Nikki Klemmer, 615-963-1310
[email protected]

KEYWORDS:   United States  North America  Tennessee

INDUSTRY KEYWORDS:   Health  Oncology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.